Zoetis Inc. (NYSE:ZTS) Stock Holdings Raised by Alberta Investment Management Corp

Alberta Investment Management Corp raised its stake in Zoetis Inc. (NYSE:ZTS) by 2,050.0% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 30,100 shares of the company’s stock after purchasing an additional 28,700 shares during the period. Alberta Investment Management Corp’s holdings in Zoetis were worth $4,904,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. AMF Tjanstepension AB boosted its holdings in shares of Zoetis by 23.4% in the 3rd quarter. AMF Tjanstepension AB now owns 105,376 shares of the company’s stock valued at $20,594,000 after buying an additional 20,001 shares during the period. Howard Capital Management Group LLC boosted its holdings in shares of Zoetis by 0.8% in the 3rd quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company’s stock valued at $20,489,000 after buying an additional 883 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in shares of Zoetis by 8.0% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 55,696 shares of the company’s stock valued at $10,882,000 after buying an additional 4,107 shares during the period. Whittier Trust Co. of Nevada Inc. boosted its holdings in shares of Zoetis by 10.6% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,966 shares of the company’s stock valued at $579,000 after buying an additional 284 shares during the period. Finally, Raleigh Capital Management Inc. boosted its holdings in shares of Zoetis by 128.5% in the 3rd quarter. Raleigh Capital Management Inc. now owns 361 shares of the company’s stock valued at $71,000 after buying an additional 203 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 0.3 %

Shares of NYSE:ZTS opened at $156.92 on Thursday. The company has a 50 day moving average of $167.29 and a 200-day moving average of $178.29. The firm has a market cap of $70.27 billion, a P/E ratio of 28.69, a P/E/G ratio of 2.71 and a beta of 0.90. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. The company had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. As a group, analysts anticipate that Zoetis Inc. will post 6.06 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.27%. Zoetis’s payout ratio is currently 36.56%.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. The trade was a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

ZTS has been the subject of several research reports. Piper Sandler decreased their price target on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a report on Monday, February 10th. Morgan Stanley decreased their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Leerink Partners initiated coverage on shares of Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price for the company. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, UBS Group initiated coverage on shares of Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 target price for the company. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $214.90.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.